Figure 4

EGFRvIII-expressing patient-derived glioma cells were more sensitive to Nimotuzumab. (A) Expression levels of wtEGFR (170 kDa) and EGFRvIII (145 kDa) were analyzed in primary GBM xenografts (GBM6 and 10) and in local patient-derived high grade primary GBMs, NNI37 and 41. Loading controls were performed with Hsp70. The primary GBM xenografts, GBM6 and 10 (B and C) and local patient-derived primary GBMs, NNI37 and 41 (D and E) were treated with TMZ (500 μM), rapamycin (0.1 mM), Nimotuzumab (0.013 mM) or a combination treatment of Nimotuzumab and rapamycin for 24 h and then cell viabilities were assessed by CCK-8 assay. Data are presented as mean ± SEM. Combination group was compared to Nimotuzumab single treatment for each cell type *p < 0.05, **p < 0.01, ***p < 0.001.